Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
408 | 16067 | 37.8 | 78% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
118 | 66796 | JOURNAL OF LIPID RESEARCH//HIGH DENSITY LIPOPROTEIN//STATINS |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
233 | 3776 | STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN |
3781 | 1833 | FLUVASTATIN//PLEIOTROPIC EFFECTS//HMG COA REDUCTASE INHIBITOR |
4101 | 1771 | OATP1B1//SLCO1B1//OATP |
6263 | 1442 | PRAVASTATIN//HMG COA REDUCTASE INHIBITOR//COMPACTIN |
8325 | 1195 | LAROPIPRANT//NIACIN//HM74A |
9022 | 1128 | LOVASTATIN//BB BIOCYT//PEDIAT PNEUMONOL ALLERG DIS HEMATOL |
10393 | 1001 | FENOFIBRIC ACID//FENOFIBRATE//FIBRATES |
10828 | 964 | STATIN MYOPATHY//STATIN INTOLERANCE//MYALGIA |
11704 | 897 | EZETIMIBE//CHOLESTEROL ABSORPTION INHIBITOR//COLESEVELAM |
13885 | 743 | P DIS TB INTERNAL MED//3 HYDROXY 3 METHYLGLUTARYL CO ENZYME A REDUCTASE INHIBITOR//INTER PROGRAM IMMUNOL |
18625 | 477 | NK 104//PITAVASTATIN//CAS 147526 32 7 |
18678 | 474 | ROSUVASTATIN CALCIUM//ATORVASTATIN CALCIUM//EZETIMIBE GLUCURONIDE |
21265 | 366 | PROBUCOL//AGI 1067//SUCCINOBUCOL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | STATINS | Author keyword | 890 | 37% | 12% | 1896 |
2 | EZETIMIBE | Author keyword | 494 | 65% | 3% | 466 |
3 | SIMVASTATIN | Author keyword | 406 | 41% | 5% | 780 |
4 | STATIN | Author keyword | 388 | 37% | 5% | 837 |
5 | ATORVASTATIN | Author keyword | 358 | 41% | 4% | 684 |
6 | PRAVASTATIN | Author keyword | 291 | 53% | 2% | 387 |
7 | HMG COA REDUCTASE INHIBITORS | Author keyword | 258 | 55% | 2% | 322 |
8 | ROSUVASTATIN | Author keyword | 192 | 47% | 2% | 299 |
9 | HMG COA REDUCTASE INHIBITOR | Author keyword | 183 | 54% | 1% | 234 |
10 | FLUVASTATIN | Author keyword | 150 | 52% | 1% | 204 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | STATINS | 890 | 37% | 12% | 1896 | Search STATINS | Search STATINS |
2 | EZETIMIBE | 494 | 65% | 3% | 466 | Search EZETIMIBE | Search EZETIMIBE |
3 | SIMVASTATIN | 406 | 41% | 5% | 780 | Search SIMVASTATIN | Search SIMVASTATIN |
4 | STATIN | 388 | 37% | 5% | 837 | Search STATIN | Search STATIN |
5 | ATORVASTATIN | 358 | 41% | 4% | 684 | Search ATORVASTATIN | Search ATORVASTATIN |
6 | PRAVASTATIN | 291 | 53% | 2% | 387 | Search PRAVASTATIN | Search PRAVASTATIN |
7 | HMG COA REDUCTASE INHIBITORS | 258 | 55% | 2% | 322 | Search HMG+COA+REDUCTASE+INHIBITORS | Search HMG+COA+REDUCTASE+INHIBITORS |
8 | ROSUVASTATIN | 192 | 47% | 2% | 299 | Search ROSUVASTATIN | Search ROSUVASTATIN |
9 | HMG COA REDUCTASE INHIBITOR | 183 | 54% | 1% | 234 | Search HMG+COA+REDUCTASE+INHIBITOR | Search HMG+COA+REDUCTASE+INHIBITOR |
10 | FLUVASTATIN | 150 | 52% | 1% | 204 | Search FLUVASTATIN | Search FLUVASTATIN |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PRAVASTATIN | 1255 | 50% | 11% | 1825 |
2 | SIMVASTATIN | 928 | 43% | 10% | 1666 |
3 | COA REDUCTASE INHIBITORS | 665 | 45% | 7% | 1105 |
4 | ATORVASTATIN | 576 | 38% | 7% | 1198 |
5 | PRIMARY HYPERCHOLESTEROLEMIA | 574 | 75% | 3% | 415 |
6 | LOVASTATIN | 563 | 49% | 5% | 835 |
7 | AVERAGE CHOLESTEROL LEVELS | 451 | 51% | 4% | 626 |
8 | HMG COA REDUCTASE | 375 | 35% | 5% | 857 |
9 | STATINS | 361 | 31% | 6% | 979 |
10 | SCANDINAVIAN SIMVASTATIN SURVIVAL | 282 | 55% | 2% | 357 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL LIPIDOLOGY | 28 | 23% | 1% | 110 |
2 | ATHEROSCLEROSIS SUPPLEMENTS | 11 | 19% | 0% | 51 |
3 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 7 | 13% | 0% | 48 |
4 | CURRENT ATHEROSCLEROSIS REPORTS | 6 | 10% | 0% | 57 |
5 | JOURNAL OF CARDIOVASCULAR RISK | 3 | 11% | 0% | 27 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis | 2011 | 326 | 30 | 70% |
Membrane transporters in drug development | 2010 | 789 | 205 | 35% |
Impact of OATP transporters on pharmacokinetics | 2009 | 262 | 147 | 86% |
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake | 2011 | 164 | 220 | 79% |
Statins and All-Cause Mortality in High-Risk Primary Prevention A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants | 2010 | 188 | 31 | 84% |
Statin myotoxicity: A review of genetic susceptibility factors | 2014 | 27 | 127 | 77% |
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance | 2006 | 325 | 143 | 88% |
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives | 2010 | 207 | 121 | 60% |
Statins and cancer risk - A meta-analysis | 2006 | 329 | 42 | 83% |
Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials | 1999 | 758 | 41 | 73% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL PHARMACOKINET | 35 | 39% | 0.4% | 71 |
2 | INTERNAL MED CLIN PHARMACOL | 22 | 35% | 0.3% | 51 |
3 | OFF HLTH PROMOT DIS PREVENT | 18 | 55% | 0.1% | 23 |
4 | HEART DIS PREVENT CLIN | 14 | 64% | 0.1% | 14 |
5 | SECT ATHEROSCLEROSIS LIPID | 9 | 83% | 0.0% | 5 |
6 | LIPID CLIN | 9 | 13% | 0.4% | 61 |
7 | RIKEN INNOVAT | 8 | 43% | 0.1% | 15 |
8 | VASC MED ATHEROSCLEROSIS UNIT | 8 | 29% | 0.1% | 24 |
9 | TOKYO NEW DRUG S 1 | 8 | 60% | 0.1% | 9 |
10 | ANAL COST EFFECT CARE | 8 | 39% | 0.1% | 15 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000015039 | MEDICATION ADHERENCE//JOURNAL OF HUMAN HYPERTENSION//BLOOD PRESSURE CONTROL |
2 | 0.0000014217 | CHOLESTERYL ESTER TRANSFER PROTEIN//JOURNAL OF LIPID RESEARCH//HIGH DENSITY LIPOPROTEIN |
3 | 0.0000011512 | POLICOSANOL//OCTACOSANOL//DECALEPIS HAMILTONII |
4 | 0.0000010108 | PLANT STEROLS//PHYTOSTEROLS//SITOSTANOL |
5 | 0.0000009842 | BOVINE HIPPOCAMPUS//SEROTONIN1A RECEPTOR//P MPPF |
6 | 0.0000008979 | INFLAMMASOME//C REACTIVE PROTEIN//NLRP3 |
7 | 0.0000008852 | INTIMA MEDIA THICKNESS//CAROTID ARTERIES//VASA VASORUM |
8 | 0.0000008688 | PEPT1//PEPT2//HPEPT1 |
9 | 0.0000007866 | LIPOPROTEINA//APOLIPOPROTEINA//LIPOPROTEIN A |
10 | 0.0000007838 | LOX 1//OXIDIZED LDL//SCAVENGER RECEPTOR |